Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
BörsenkürzelFLGT
Name des UnternehmensFulgent Genetics Inc
IPO-datumSep 28, 2016
CEOHsieh (Ming)
Anzahl der mitarbeiter1313
WertpapierartOrdinary Share
GeschäftsjahresendeSep 28
Addresse4399 Santa Anita Ave
StadtEL MONTE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl91731
Telefon16263500537
Websitehttps://www.fulgentgenetics.com/
BörsenkürzelFLGT
IPO-datumSep 28, 2016
CEOHsieh (Ming)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten